The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
Beyond expanding drug discovery, Lilly plans to harness the supercomputer to reduce development cycles. Credit: Vink Fan via Shutterstock.com.
Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles, marking one of the largest AI partnerships in the pharma industry to date.
According to Eli Lilly, the supercomputer – powered by more than a thousand graphics processing units (GPUs) – will serve as an “AI factory”, a computing infrastructure that manages the entire AI lifecycle. The supercomputer will run on renewable electricity and be housed within Lilly facilities. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
